EIF2AK4突变在肺动脉高压患者中的检出情况
该研究对北美30个中心诊断为特发性肺动脉高压(IPAH,72例)或遗传性肺动脉高压(HPAH,9例)的81例患者进行基因检测,先筛查BMPR2,阴性者再筛查ACVRL1、ENG、CAV1、KCNK3,全部阴性者(66例)再测EIF2AK4。结果在9例HPAH中检出1例(11.1%)新型纯合EIF2AK4突变(c.257+4A>C),72例IPAH中无biallelic EIF2AK4突变;BMPR2致病突变在IPAH中为8/72(11.1%),在HPAH中为6/9(66.7%)。作者认为致病性biallelic EIF2AK4突变在HPAH中罕见,但检出有助于区分HPAH与遗传性PVOD或PCH。
要点
- HPAH患者中可检出致病性biallelic EIF2AK4突变,但频率低(1/9,11.1%)。
- 72例IPAH患者中未发现biallelic EIF2AK4突变。
- 检出致病性biallelic EIF2AK4突变有助于鉴别HPAH与遗传性PVOD或PCH。
核心结论
- 致病性biallelic EIF2AK4突变在临床诊断为HPAH的患者中罕见,但检出可帮助鉴别HPAH与遗传性PVOD或PCH。
研究设计与样本
- 研究纳入北美30个医学中心临床诊断为IPAH(n=72)或HPAH(n=9)的81例患者。
- 先对81例患者行BMPR2基因Sanger测序及缺失/重复分析,BMPR2突变阴性者(n=67)再测ACVRL1、ENG、CAV1和KCNK3。
- 全部已知PAH基因阴性者(n=66)再行EIF2AK4测序,并评估突变致病性、回顾携带致病突变患者的临床特征。
主要发现
- BMPR2致病突变见于8/72(11.1%)IPAH患者和6/9(66.7%)HPAH患者。
- 在1/9(11.1%)诊断为HPAH的患者中检出新型纯合EIF2AK4突变(c.257+4A>C)。
- 该新型EIF2AK4突变(c.257+4A>C)在两姐妹中为纯合状态,二人均患重度肺动脉高压。
- 72例IPAH患者中无一携带biallelic EIF2AK4突变。
关键数值与推荐
- BMPR2致病突变:IPAH 8/72(11.1%),HPAH 6/9(66.7%)。
- 致病性EIF2AK4突变:HPAH 1/9(11.1%),IPAH 0/72。
- 检出的EIF2AK4突变为c.257+4A>C,纯合状态。
临床怎么用
- 对临床诊断为HPAH且已知PAH基因阴性者,可考虑检测EIF2AK4以助鉴别遗传性PVOD或PCH。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differentiating pulmonary venoocclusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) from idiopathic pulmonary arterial hypertension (IPAH) or heritable pulmonary arterial hypertension (HPAH) is important clinically. Mutations in eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4) cause heritable PVOD and PCH, whereas mutations in other genes cause HPAH. The aim of this study was to describe the frequency of pathogenic EIF2AK4 mutations in patients diagnosed clinically with IPAH or HPAH. METHODS: Sanger sequencing and deletion/duplication analysis were performed to detect mutations in the bone morphogenetic protein receptor type II (BMPR2) gene in 81 patients diagnosed at 30 North American medical centers with IPAH (n = 72) or HPAH (n = 9). BMPR2 mutation-negative patients (n = 67) were sequenced for mutations in four other genes (ACVRL1, ENG, CAV1, and KCNK3) known to cause HPAH. Patients negative for mutations in all known PAH genes (n = 66) were then sequenced for mutations in EIF2AK4. We assessed the pathogenicity of EIF2AK4 mutations and reviewed clinical characteristics of patients with pathogenic EIF2AK4 mutations. RESULTS: Pathogenic BMPR2 mutations were identified in 8 of 72 (11.1%) patients with IPAH and 6 of 9 (66.7%) patients with HPAH. A novel homozygous EIF2AK4 mutation (c.257+4A>C) was identified in 1 of 9 (11.1%) patients diagnosed with HPAH. The novel EIF2AK4 mutation (c.257+4A>C) was homozygous in two sisters with severe pulmonary hypertension. None of the 72 patients with IPAH had biallelic EIF2AK4 mutations. CONCLUSIONS: Pathogenic biallelic EIF2AK4 mutations are rarely identified in patients diagnosed with HPAH. Identification of pathogenic biallelic EIF2AK4 mutations can aid clinicians in differentiating HPAH from heritable PVOD or PCH.
引用
- Best DH, Sumner KL, Smith BP, et al. EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension. Chest. 2016. PMID: 27884767. doi:10.1016/j.chest.2016.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。